BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang L, Su G, Zhao X, Cai Y, Cai X, Zhang J, Liu J, Wang T, Wang J. Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk. Tumour Biol 2014;35:1139-42. [PMID: 24014088 DOI: 10.1007/s13277-013-1152-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Mao F, Niu XB, Gu S, Ji L, Wei BJ, Wang HB. CTLA-4 +49A/G Polymorphism Increases the Susceptibility to Bladder Cancer in Chinese Han Participants: A Case-Control Study. Dis Markers 2020;2020:8143158. [PMID: 33335608 DOI: 10.1155/2020/8143158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Corradi RB, LaRosa S, Jebiwott S, Murray KS, Rosenzweig B, Somma AJ, Gomez RS, Scherz A, Kim K, Coleman JA. Effectiveness of the combination of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen 4 in a preclinical mouse model of urothelial carcinoma. Int J Urol 2019;26:414-22. [PMID: 30659668 DOI: 10.1111/iju.13878] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Breyer J, Burger M, Otto W. Immunotherapy in urothelial carcinoma: fade or future standard? Transl Androl Urol 2016;5:662-7. [PMID: 27785423 DOI: 10.21037/tau.2016.04.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Fahmy O, Khairul-Asri MG, Stenzl A, Gakis G. The current status of checkpoint inhibitors in metastatic bladder cancer. Clin Exp Metastasis. 2016;33:629-635. [PMID: 27380916 DOI: 10.1007/s10585-016-9807-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
5 Smith SG, Zaharoff DA. Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy 2016;8:351-65. [PMID: 26860539 DOI: 10.2217/imt.15.122] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
6 Aoun F, Kourie HR, Sideris S, Roumeguère T, Velthoven RV, Gil T. Checkpoint inhibitors in bladder and renal cancers: results and perspectives. Immunotherapy 2015;7:1259-71. [DOI: 10.2217/imt.15.91] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
7 Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015;68:267-79. [PMID: 25824720 DOI: 10.1016/j.eururo.2015.02.032] [Cited by in Crossref: 147] [Cited by in F6Publishing: 161] [Article Influence: 18.4] [Reference Citation Analysis]
8 Guo YF, Qiu JX, Guo F, Liu Y, Shang MH. CTLA4 polymorphisms and de novo malignancy risk after renal transplantation in Chinese recipients. Biomed Res Int 2015;2015:986780. [PMID: 25667935 DOI: 10.1155/2015/986780] [Reference Citation Analysis]